{
  "abstract": "Background and Importance Intravitreal therapies are the standard of care for macular diseases, but real-world practice often differs from clinical trials. The introduction of new agents and rising patient complexity create challenges for healthcare systems. Understanding prescribing trends in routine hospital practice is essential to guide therapeutic decisions and anticipate demand.Aim and Objectives To analyse the evolution of intravitreal treatment prescribing patterns in patients with macular diseases between 2021 and 2024, assessing the impact of newly introduced therapeutic options and the increasing complexity of treated patients.Material and Methods We conducted a retrospective observational study including all patients who received intravitreal injections between January 2021 and December 2024. Data extraction, integration, and processing were performed using Power BI as part of a multidisciplinary project. Descriptive statistics and simple linear regression were applied to evaluate temporal trends (p<0.05).Results A total of 3,223 patients received 31,826 intravitreal injections. Bevacizumab was the most frequently prescribed drug (58.73%, n=18,690), followed by aflibercept (25.99%, n=8,270) and ranibizumab (9.01%, n=2,869).The number of treated patients increased from 1,330 in 2021 to 1,911 in 2024 (+43.7%), while total injections rose from 6,134 to 9,345 (+52.3%).Between 2023 and 2024, bevacizumab and ranibizumab use decreased by 13.78% and 1.24%, respectively, whereas aflibercept prescriptions increased by 13.38%. Notable findings included a rise in brolucizumab use (from 96 to 311 injections) and the introduction of faricimab (419 injections in 179 patients). Dexamethasone use increased by 14.63%, while fluocinolone remained stable.Regarding clinical complexity, treatment lines were distributed as follows: 657 patients in first-line, 411 in second, 180 in third, 70 in fourth, and 26 in fifth-line. The mean number of treatment lines per patient increased from 1.35 (2021) to 1.76 (2024), showing a statistically significant upward trend (annual coefficient: 0.130; 95% CI: 0.048–0.212; standard error: 0.019; p=0.021).Conclusion and Relevance Findings demonstrate a progressive increase in care demand, accompanied by changes in prescribing trends, with greater adoption of innovative therapies and higher clinical complexity among treated patients. These results underscore the importance of integrating data analytics into daily practice to optimise therapeutic decision making and anticipate the growing healthcare demand in ophthalmology.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "Y Rioja"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "A Ribed Sánchez"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "MA María Pilar"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "P Ruiz Briones"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "A Carrillo Burdallo"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "MB María"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "A Prieto Romero"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "X Garcia Gonzalez"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "D Gomez Costas"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "Á Gimenez Manzorro"
    },
    {
      "affiliations": [
        "Hospital General Universitario Gregorio Marañón, Hospital Pharmacy, Madrid, Spain"
      ],
      "name": "A Herranz Alonso"
    }
  ],
  "title": "2SPD-007 Trends in intravitreal therapy prescribing: insights from real-world data (2021–2024)",
  "uid": "51c9d198-88ee-54f8-820c-5f301b10cbb5"
}